As of July 26, 2026, Larimar Therapeutics's top three insider holders are James E Flynn (Director, 35.61Mn shares), Thomas Edward Hamilton (Director, 664.80K shares), Carole Ben-Maimon (President And Ceo, 368.28K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| James E Flynn | - | 0 | 35,606,974 | 02 Mar, 2026 |
| Michael Celano | Chief Financial Officer | 215,785 | 0 | 27 Jan, 2026 |
| Joseph Truitt | - | 2,750 | 0 | 18 May, 2023 |
| Carole Ben-Maimon | President And Ceo | 368,276 | 0 | 27 Jan, 2026 |
| Russell Clayton | Chief Medical Officer | 71,443 | 0 | 27 Jan, 2026 |
| Thomas Edward Hamilton | - | 664,798 | 0 | 02 Mar, 2026 |
| Gopi Shankar | Chief Development Officer | 76,443 | 0 | 27 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 27 Feb, 2026 | Thomas Edward Hamilton | Common Stock | A | 100,000 | $5.00 | 664,798 | D | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,010 | $5.00 | 10,622,928 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 1,084,012 | $5.00 | 10,622,957 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 831,978 | $5.00 | 8,153,107 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 831,978 | $5.00 | 8,153,107 | I | P |
| 27 Feb, 2026 | James E Flynn | Common Stock | A | 831,978 | $5.00 | 8,153,107 | I | P |